Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Poynard

Showing results (11-20 of 272) with videos related to

Pageof 28
Sort By:
Gastroenterologie Clinique Et Biologique|October 31, 2003
[Non-alcoholic steatosis: limits of current knowledge and lessons for hepatologists]Vlad Ratziu, Thierry Poynard
Journal of Hepatology|January 5, 2005
NASH: a hidden and silent fibroser finally revealed?Vlad Ratziu, Thierry Poynard
Annals of Internal Medicine|November 19, 2009
Similarities and differences between REPEAT and EPIC3Thierry Poynard, Eugene Shiff
Gastroenterology|November 13, 2004
Truth is not determined by a majority voteRonald L Koretz, Thierry Poynard
Antiviral Therapy|June 3, 2010
Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosisThierry Poynard, Nezam H Afdhal
Annals of Hepatology|April 20, 2004
Risk factors for liver fibrosis progression in patients with chronic hepatitis CMercedes de Torres, Thierry Poynard
Journal of Hepatology|February 8, 2011
FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpretedMona Munteanu, Vlad Ratziu, Thierry Poynard
Alimentary Pharmacology & Therapeutics|February 13, 2019
Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' replyThierry Poynard, Olivier Deckmyn, Chantal Housset, et al.
Gastroenterology|November 28, 2002
Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failureVlad Ratziu, Maya Nourani, Thierry Poynard
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 19, 2006
Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis groupJohn McHutchison, Thierry Poynard, Nezam Afdhal, et al.
Pageof 28

Showing results (11-20 of 272) with videos related to

Sort By:
Pageof 28
Gastroenterologie Clinique Et Biologique|October 31, 2003
[Non-alcoholic steatosis: limits of current knowledge and lessons for hepatologists]Vlad Ratziu, Thierry Poynard
Journal of Hepatology|January 5, 2005
NASH: a hidden and silent fibroser finally revealed?Vlad Ratziu, Thierry Poynard
Annals of Internal Medicine|November 19, 2009
Similarities and differences between REPEAT and EPIC3Thierry Poynard, Eugene Shiff
Gastroenterology|November 13, 2004
Truth is not determined by a majority voteRonald L Koretz, Thierry Poynard
Antiviral Therapy|June 3, 2010
Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosisThierry Poynard, Nezam H Afdhal
Annals of Hepatology|April 20, 2004
Risk factors for liver fibrosis progression in patients with chronic hepatitis CMercedes de Torres, Thierry Poynard
Journal of Hepatology|February 8, 2011
FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpretedMona Munteanu, Vlad Ratziu, Thierry Poynard
Alimentary Pharmacology & Therapeutics|February 13, 2019
Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' replyThierry Poynard, Olivier Deckmyn, Chantal Housset, et al.
Gastroenterology|November 28, 2002
Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failureVlad Ratziu, Maya Nourani, Thierry Poynard
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 19, 2006
Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis groupJohn McHutchison, Thierry Poynard, Nezam Afdhal, et al.
Pageof 28